Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab

Arthritis Care and Research

Volumn 61, Issue 8, 2009, Pages 1032-1036

  Braun, Jürgen ^a   Van Der Heijde, Désirée ^b   Doyle, Mittie K ^c,d   Han, Chenglong ^c   Deodhar, Atul ^e   Inman, Robert ^f   De Vlam, Kurt ^g   Burmester, Gerd R ^h   Van Den Bosch, Filip ⁱ   Xu, Stephen ^c   Visvanathan, Sudha ^c   Rahman, Mahboob U ^d  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CENTOCOR INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; INFLIXIMAB; INTERLEUKIN 6; PLACEBO;

ADULT; ANEMIA; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; DRUG EFFECT; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; GENERAL CONDITION IMPROVEMENT; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEX DIFFERENCE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADULT; ANEMIA; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FATIGUE; FEMALE; HEALTH STATUS; HEMOGLOBINS; HUMANS; MALE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 68149172593     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.24865     Document Type: Article

References (16)

1. Khan MA. Thoughts concerning the early diagnosis of ankylosing spondylitis and related diseases. Clin Exp Rheumatol 2002;20 Suppl 28:S6-10.
2. McGonagle D, Marzo-Ortega H, Benjamin M, Emery P. Report on the second international enthesitis workshop. Arthritis Rheum 2003;48:896-905. (Pubitemid 36418231)
3. Zhang X, Aubin JE, Inman RD. Molecular and cellular biology of new bone formation: insights into the ankylosis of ankylosing spondylitis. Curr Opin Rheumatol 2003;15:387-393 (Pubitemid 36774249)
4. Wolfe F, Michaud K. Anemia and renal function in patients with rheumatoid arthritis. J Rheumatol 2006;33:1516-1522 (Pubitemid 44168821)
5. Boonen A. Socioeconomic consequences of ankylosing spondylitis. Clin Exp Rheumatol 2002;20 Suppl 28:S23-6.
6. Vreugdenhil G, Lowenberg B, Van Eijk HG, Swaak AJ. Tumor necrosis factor α is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis. Eur J Clin Invest 1992;22:488-493
7. Francois RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor α in two patients with early disease and transforming growth factor β in three more advanced cases. Ann Rheum Dis 2006;65:713-720 (Pubitemid 43799168)
8. Voulgari PV, Kolios G, Papadopoulos GK, Katsaraki A, Seferiadis K, Drosos AA. Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol 1999;92:153-160 (Pubitemid 29362545)
9. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-1276 (Pubitemid 39069926)
10. Roy CN, Andrews NC. Anemia of inflammation: the hepcidin link. Curr Opin Hematol 2005;12:107-111
11. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-452
12. Thiefin G, Beaugerie L. Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. Joint Bone Spine 2005;72:286-294 (Pubitemid 40994974)
13. Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al, and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-591
14. Braun J, Landewe R, Hermann KG, Han J, Yan S, Williamson P, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-1652
15. Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008;67:511-517
16. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003;48:2224-2233 (Pubitemid 36959203)